Serum human glandular kallikrein-2 protease levels predict the presence of prostate cancer among men with elevated prostate-specific antigen

Journal of Clinical Oncology

Volumn 18, Issue 5, 2000, Pages 1036-1042

  Nam, Robert K ^a   Diamandis, Eleftherios P ^a   Toi, Ants ^a   Trachtenberg, John ^a   Magklara, Angeliki ^a   Scorilas, Andreas ^a   Papnastasiou, Panayotis A ^a   Jewett, Michael A S ^a   Narod, Steven A ^a  

^a MOUNT SINAI HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; PROTEINASE; TISSUE KALLIKREIN;

AGED; ARTICLE; CANCER DIAGNOSIS; CANCER RISK; CANCER SCREENING; CONTROLLED STUDY; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT SELECTION; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL;

EID: 0033993446     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/jco.2000.18.5.1036     Document Type: Article

References (44)

1. Potosky AL, Miller BA, Albertsen PC, et al: The role of increasing detection in the rising incidence of prostate cancer. JAMA 273:548-552, 1995
2. Canadian Cancer Statistics 1997. Toronto, Canada, National Cancer Institute, 1997
3. Catalona WJ, Smith DS: Cancer recurrence and survival rates after anatomic radical retropubic prostatectomy for prostate cancer: Intermediate-term results. J Urol 160:2428-2434, 1998
4. Dillioglugil O, Leibman BD, Kattan MW, et al: Hazard rates for progression after radical prostatectomy for clinically localized prostate cancer. Urology 50:93-99, 1997
5. Zincke H, Bergstralh EJ, Blute ML, et al: Radical prostatectomy for clinically localized prostate cancer: Long-term results of 1143 patients from a single institution. J Clin Oncol 12:2254-2263, 1994
6. Epstein JI, Partin AW, Sauvageot J, et al: Prediction of progression following radical prostatectomy. Am J Surg Pathol 20:286-292, 1996
7. Catalona WJ, Smith DS, Ratiff TL, et al: Detection of organ-confined prostate cancer is increased through prostate-specific antigen-based screening. JAMA 270:948-954, 1993
8. Lu-Yao GL, Yao SL: Population-based study of long-term survival in patients with clinically localised prostate cancer. Lancet 349:906-910, 1997
9. Gerber GS, Thisted RA, Scardino PT, et al: Results of radical prostatectomy in men with clinically localized prostate cancer. JAMA 276:615-619, 1996
10. Vanchieri C: Prostate cancer screening trials. Fending off critics to recruit men. J Natl Cancer Inst 90:10-12, 1998
11. Schroder FH, Bangma CH: The European randomized study of screening for prostate cancer (ERSPC). Br J Urol 79:68-71, 1997
12. Crawford ED, DeAntoni EP: PSA as a screening test for prostate cancer. Urol Clin North Am 20:637-646, 1993
13. Oesterling JE: Prostate specific antigen: A critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. J Urol 145:907-923, 1991
14. Narod SA, Dupont A, Cusan L, et al: The impact of family history on early detection of prostate cancer. Nat Med 1:99-101, 1995
15. Gann PH, Hennekens CH, Stampfer MJ: A prospective evaluation of plasma prostate-specific antigen for detection of prostatic cancer. JAMA 273:289-294, 1995
16. Nam RK, Klotz LH, Jewett MAS, et al: PSA velocity as a measure of the natural history of prostate cancer: Defining a "rapid riser" subset. Br J Urol 81:100-104, 1998
17. Catalona WJ, Smith DS, Wolfert RL, et al: Evaluation of percentage of free serum prostate-specific antigen to improve specificity of prostate cancer screening. Am J Med 274:1214-1220, 1995
18. Jung K, Meyer A, Lein M, et al: Ratio of free-to-total prostate specific antigen in serum cannot distinguish patients with prostate cancer from those with chronic inflammation of the prostate. J Urol 159:1595-1598, 1998
19. Meshref AW, Bazinet M, Trudel C, et al: Role of prostate-specific antigen density after applying age-specific prostate-specific antigen reference ranges. Urology 45:972-979, 1995
20. McCormack RT, Rittenhouse HG, Finlay JA, et al: Molecular forms of prostate-specific antigen and the human kallikrein gene family: A new era. Urology 45:729-744, 1995
21. Young C-F, Andrews PE, Montgomery BT, et al: Tissue-specific and hormonal regulation of human prostate-specific glandular kallikrein. Biochemistry 31:818-824, 1992
22. Henttu P, Lukkarinen O, Vihko P: Expression of the gene coding for human prostate-specific antigen and related hGK-1 in benign and malignant tumors of the human prostate. Int J Cancer 45:654-660, 1990
23. Murtha P, Tindall DJ, Young C-F: Androgen induction of a human prostate-specific kallikrein hKLK2: Characterization of an androgen response element in the 5′ promoter region of the gene. Biochemistry 32:6459-6464, 1993
24. Reigman PH, Vlietstra RJ, Suurmeijer L, et al: Characterization of the human kallikrein locus. Genomics 14:6-11, 1992
25. Schedlich LJ, Bennetts BH, Morris BJ: Primary structure of human glandular kallikrein gene. DNA 6:429-437, 1987
26. Lovgren J, Rajakoski K, Karp M, et al: Activation of the zymogen form of prostate-specific antigen by human glandular kallikrein 2. Biochem Biophys Res Commun 238:549-555, 1997
27. Lilja H: A kallikrein-like serine protease in prostatic fluid cleaves the predominant seminal vesicle protein. J Clin Invest 76:1899-1903, 1985
28. Finlay JA, Evans CL, Day JR, et al: Development of monoclonal antibodies specific for human glandular kallikrein (hK2): Development of a dual antibody immunoassay for hK2 with negligible prostate-specific antigen cross-reactivity. Urology 51:804-809, 1998
29. Darson MF, Pacelli A, Roche P, et al: Human glandular kallikrein 2 (hK2) expression in prostatic intraepithelial neoplasia and adenocarcinoma: A novel prostate cancer marker. Urology 49:857-862, 1997
30. Barry MJ, Fowler FJJ, O'Leary MP, et al: The American Urological Association symptom index for benign prostatic hyperplasia: The Measurement Committee of the American Urological Association. J Urol 148:1549-1557, 1992
31. Gleason DF, Mellinger GT: Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging. J Urol 111:58-64, 1974
32. Black MH, Magklara A, Obiezu C, et al: Development of an ultrasensitive immunoassay for human glandular kallikrein (hK2) with no cross reactivity from prostate specific antigen (PSA). Clin Chem 45:790-799, 1999
33. Kwiatkowski MK, Recker F, Piironen T, et al: In prostatism patients the ratio of human glandular kallikrein to free PSA improves the discrimination between prostate cancer and benign hyperplasia within the diagnostic "gray zone" of total PSA 4 to 10 ng/mL. Urology 52:360-365, 1998
34. Magklara A, Scorilas A, Catalona W, et al: The combination of human glandular kallikrein (hK2) and free PSA enhances the discrimination between prostate cancer and benign prostatic hyperplasia in patients with moderately increased total PSA. Clin Chem 45:1960-1966, 1999
35. Catalona WJ, Partin AW, Slawin KM, et al: Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: A prospective multi-center clinical trial. JAMA 279:1542-1547, 1998
36. Mettlin C, Murphy GP, Babaian RJ, et al: The results of a five-year early prostate detection intervention: Investigators of the American Cancer Society National Prostate Cancer Detection Project. Cancer 77:150-159, 1996
37. Smith JA, Scardino PT, Resnick MI, et al: Transrectal ultrasound versus digital rectal examination for the staging of carcinoma of the prostate: Results of prospective, multi-institutional trial. J Urol 157:902-906, 1997
38. Metz CE: Basic principles of ROC analysis. Semin Nucl Med 8:283-298, 1978
39. Bjork T, Bjartell A, Abrahamsson PA, et al: Alpha 1-antichymotrypsin production in PSA-producing cells is common in prostate cancer but rare in benign prostatic hyperplasia. Urology 43:427-434, 1994
40. Bostwick DG: High grade prostatic intraepithelial neoplasia: The most likely precursor of prostate cancer. Cancer 75:1823-1836, 1995
41. Bostwick DG, Pacelli A, Lopez-Beltran A: Molecular biology of prostatic intraepithelial neoplasia: The most likely precursor of prostate cancer. Prostate 29:117-134, 1996
42. Albertsen PC, Fryback DG, Storer BE, et al: Long-term survival among men with conservatively treated localized prostate cancer. JAMA 274:626-631, 1995
43. Keetch DW, Catalona WJ, Smith DS: Serial prostatic biopsies in men with persistently elevated serum prostate specific antigen values. J Urol 151:1571-1574, 1994
44. Catalona WJ, Smith DS, Ornstein DK: Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4.0 ng/mL and benign prostate examination: Enhancement of specificity with free PSA measurements. JAMA 277:1452-1455, 1997